Genscript Biotech Corporation

As of December 31, 2025, Genscript Biotech Corporation carries a market capitalization of 27.13B, placing it among publicly traded companies globally. Its enterprise value stands at 22.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genscript Biotech Corporation's next confirmed earnings release is scheduled for March 24, 2027.

As of December 31, 2025, Genscript Biotech Corporation has 2.18B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Genscript Biotech Corporation maintains a current ratio of 1.50, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Genscript Biotech Corporation's stock has gained approximately 104.60% over the past 52 weeks. The 50-day moving average sits at 35.82, while the 200-day moving average is 19.00.

As of December 31, 2025, Genscript Biotech Corporation holds 6.32B in cash and equivalents against 2.01B in total debt, resulting in a net debt position of 406.07M. Total book value stands at 30.81B, with working capital of 2.79B providing operational flexibility.